10 Apr 2017 17:21
10 April 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Director Share Purchase
Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, announces that it has been notified that Markus Ziener, Non-Executive Director, has purchased 100,000 ordinary shares of 1p each ("Ordinary Shares") at a price of 21.5p per Ordinary Share.
Following this transaction, Mr Ziener holds 100,000 Ordinary Shares, representing 0.05% of the Company's issued share capital (excluding treasury shares). Mr Ziener is the Executive Managing Director of Software AG Stiftung, a 20.9% shareholder in Amryt.
Full details as required under the Market Abuse Regulation are set out below.
Notification of Transactions of Directors / Persons Discharging Managerial Responsibility and Connected Persons
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
|
Markus Ziener | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Non-Executive Director
| ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Amryt Pharma plc | ||||
b)
| LEI
| 213800BOS8WAJO2BEQ38 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
Ordinary shares of 1p each in Amryt Pharma plc
GB00BDD1LS57 | ||||
b)
| Nature of the transaction
| Purchase of shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume - Price
|
N/A (single transaction)
| ||||
e)
| Date of the transaction
| 30/03/17 | ||||
f)
| Place of the transaction
| London Stock Exchange, AIM Market (XLON)
| ||||
Enquiries:
Amryt Pharma plc | C/o KTZ Communications |
Joe Wiley, CEO Rory Nealon, CFO/COO | |
Shore Capital | +44 (0) 20 7408 4090 |
Nomad and Joint Broker | |
Bidhi Bhoma, Edward Mansfield | |
Davy | +353 (1) 679 6363 |
ESM Adviser and Joint Broker | |
John Frain, Anthony Farrell | |
Stifel | +44 (0) 20 7710 7600 |
Joint Broker | |
Jonathan Senior, Ben Maddison | |
KTZ Communications | +44 (0) 20 3178 6378 |
Katie Tzouliadis, Emma Pearson |
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
The Company recently acquired an exclusive licence to sell LOJUXTA (lomitapide), across the EU and other territories including the Middle East, North Africa, Turkey and Israel. LOJUXTA is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.
Amryt's product, AP101 (Episalvan), received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to develop AP101 (Episalvan) as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. The Company recently received regulatory clarity from the FDA and the EMA regarding its Phase 3 study of AP101 (Episalvan) in EB, which has been granted US and EU orphan drug designation, and the first study site was initiated at the end of March 2017. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease. AP102 was recently granted orphan designation in the US in acromegaly by the FDA.
The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.